Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

NCT06406816 is registered in ClinicalTrials.gov with Yongyi Zeng as lead sponsor.

NCT NCT06406816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06406816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
Lead sponsor
Yongyi Zeng
Phase
Phase 1
Overall status
Recruiting
Start date
May 6, 2024
Completion date
May 31, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma